EGFR and non-small cell lung carcinoma: For patients with advanced EGFR-mutant NSCLC, a tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) is the standard first-line therapy, but the acquired resistance to EGFR-TKIs appears after a median of 10 months [39].